{"id":35332,"date":"2018-11-13T11:17:30","date_gmt":"2018-11-13T11:17:30","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=35332"},"modified":"2018-11-13T15:57:04","modified_gmt":"2018-11-13T15:57:04","slug":"fda-updates-rilpivirine-label-for-use-during-pregnancy","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/35332","title":{"rendered":"FDA updates rilpivirine label for use during pregnancy"},"content":{"rendered":"<p><b>Simon\u00a0Collins, HIV i-Base<\/b><\/p>\n<p><strong>On 31 October 2018, the US FDA approved changes to the label for fixed dose combinations (FDC) containing rilpivirine: Odefsey (RPV\/FTC\/TAF) and Eviplera\/Complera (RPV\/FTC\/TDF).<span class=\"Apple-converted-space\">\u00a0<\/span><\/strong><\/p>\n<p>For pregnant patients who are already on an RPV-based FDC prior to pregnancy and are virologically suppressed (HIV-1 RNA less than 50 copies\/mL), one tablet, once daily may be continued.<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p>Lower exposures of rilpivirine were observed during pregnancy, therefore viral load should be monitored closely.<\/p>\n<p>A similar recommendation was recently made for rilpivirine (RPV) (trade name Edurant) as a single ARV.<\/p>\n<p>Source:<\/p>\n<p><span class=\"Apple-converted-space\">\u00a0<\/span>FDA list serve update (31 October 2018)<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Simon\u00a0Collins, HIV i-Base On 31 October 2018, the US FDA approved changes to the label for fixed dose combinations (FDC) containing rilpivirine: Odefsey (RPV\/FTC\/TAF) and Eviplera\/Complera (RPV\/FTC\/TDF).\u00a0 For pregnant patients who are already on an RPV-based FDC prior to pregnancy &hellip;<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-35332","post","type-post","status-publish","format-standard","hentry","category-antiretrovirals"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/35332","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=35332"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/35332\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=35332"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=35332"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=35332"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}